Safety shipping CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride Molemo ka ho Fetisisa Boleng bo Tlase Theko e Tlase

Ticagrelor ke lithethefatsi tsa antiplatelet tsa molomo, lebitso la eona la lebitso la Amerika ke Brilinta, 'me lebitso la eona la Europe ke Brilique. Ticagrelor ke mohanyetsi oa li-platelet adenosine diphosphate (ADP) ea fetolehang e etselitsoeng ho thibela liplatelete hore li se ke tsa khomarela 'me li etsa mali a ka lebisang ho hlaseloa ke pelo le lichapo. United States, ticagrelor e ile ea amoheloa ka lekhetlo la pele ke FDA ka July 2011 bakeng sa phekolo ea bakuli ba baholo ba nang le lefu la acute coronary syndrome (ACS). Lintlha tsa kliniki li bontša hore ticagrelor e sebetsa haholo ho feta clopidogrel ho fokotsa lefu la pelo bakeng sa bonyane likhoeli tsa 12 ka mor'a ketsahalo ea ACS. Ho phaella moo, ticagrelorChemicalbook e ile ea boela ea fokotsa liketsahalo tsa stent thrombosis (ST) ho bakuli ba neng ba amohetse li-stents ho phekola ACS. Ka Phuptjane 2020, AstraZeneca e phatlalalitse hore US Food and Drug Administration (FDA) e amohetse anticoagulant Brilinta (ticagrelor) hore e sebelisoe ho bakuli ba nang le kotsi e kholo ea lefu la methapo ea pelo (CAD) ho fokotsa kotsi ea lefu la pelo la pele. kapa kotsi ea stroke. Ka November 2020, AstraZeneca e phatlalalitse hore US Food and Drug Administration (FDA) e amohetse pontšo e ncha bakeng sa anticoagulant Brilinta (ticagrelor), hammoho le aspirin, bakeng sa phekolo ea ischemia e matla. Ho bakuli ba tšoeroeng ke lefu la pelo kapa tlhaselo ea ischemic e kotsing e kholo (TIA), e fokotsa kotsi ea ho otloa ke stroke.